Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
bioMerieux ( (FR:BIM) ) has shared an announcement.
bioMérieux has received U.S. FDA clearance for its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid, a molecular test that detects 11 common gastrointestinal pathogens in about an hour. This new panel enhances the company’s diagnostic offerings by providing a faster and more comprehensive solution, which is expected to improve patient outcomes, streamline laboratory workflows, and strengthen bioMérieux’s position in syndromic molecular testing. It offers clinicians a choice between a 22-target and an 11-target panel, allowing for more precise treatment decisions and reduced empirical treatments.
More about bioMerieux
bioMérieux is a global leader in in vitro diagnostics, established in 1963 and operating in 45 countries. The company provides diagnostic solutions for infectious diseases and contamination detection in various sectors, including agri-food and pharmaceuticals. With a presence in over 160 countries and a vast distributor network, bioMérieux achieved revenues of €3.7 billion in 2023, with over 90% of sales occurring outside France.
YTD Price Performance: 10.61%
Average Trading Volume: 40,264
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €13.39B
Learn more about BIM stock on TipRanks’ Stock Analysis page.
